Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-12-12
2006-12-12
Nguyen, Quang (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C424S093200
Reexamination Certificate
active
07148201
ABSTRACT:
The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification methods. The method of immunoaffinity purification of the invention is based on the discovery of a method for identifying antibodies that specifically bind native hpHAse (anti-native hpHAse antibodies), and anti-native hpHAse antibodies identified by this screening method. The invention also features an assay for sensitive detection of HAse activity using biotinylated hyaluronic acid (bHA). Purification and characterization of hpHAse lead to the inventors' additional discovery that hpHAse is encoded by the LuCa-1 gene, which gene is present in the human chromosome at 3p21.3, a region associated with tumor suppression. The invention additionally features methods of treating tumor-bearing patients by administration of hpHAse and/or transformation of cells with hpHAse-encoding DNA.
REFERENCES:
patent: 3945889 (1976-03-01), Mima et al.
patent: 5427779 (1995-06-01), Elsner et al.
patent: WO 88/02261 (1988-04-01), None
patent: WO 89/05329 (1989-06-01), None
patent: WO 96/03497 (1996-02-01), None
patent: WO 96/31596 (1996-10-01), None
Verma, I. M. et al. “Gene Therapy- promises, Problems and Prospects” (1997) Nature vol. 389, pp. 239-242.
Orkin, S. H. et al. “Report and Recommendations of The Panel to Assess The NIH Investment in Research on Gene Therapy” (1995).
Eck, S. L. et al “Gene-Based therapy” in The Pharmacological Basis of therapeutics, Goodman & Gilman's, McGraq-Hill, Ninth Edition, pp. 77-101, 1996.
Rozenberg, Y. et al. “Alternative Gene Delivery” S.T.P. Pharma Sci (2001) vol. 11, pp. 21-30.
Nishikawa, M. et al. “Nonviral Vectors in The New Millennium: Delivery Barrier in Gene Transfer” (2001) Hum Gene Ther vol. 12, pp. 861-870.
Balicki, D. et al. “Gene Therapy of Human Disease” (2002) Medicine vol. 81, pp. 69-86.
Csoka, T. B. et al. “Hyaluronidases in Tissue Invasion” (1997) Invasion and Metastasis vol. 17, No. 6, pp. 297-311.
Chang N. S. “Transforming Growth Factor-beta Protection of Cancer Cells Against Tumor Necrosis Factor Cytotoxicity is counteracted by Hyaluronidase” (1998) Int J Mol Med vol. 2, No. 6, pp. 653-659.
Lepperdinger, G. et al. “Hyal2—Less Active, But Nore Versatile?” (2001) Matrix Biol vol. 20, pp. 509-514.
Lin Ji et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in Vitro and in Vivo. Cancer Res. 62:2715-2720, 2002.
Patel et al. Hyaluronidase gene profiling and role of HYAL-1 overexpression in an orthotopic model of prostate cancer. Int. J. Cancer 97:416-424, 20002.
Romano et al. Latest developments in gene transfer technology: Achievements, perspectives, and controveries over therapeutic applications. Stem Cells 18: 19-39, 2000.
Dang et al. Gene therapy and translational cancer research. Clin. Cancer Res. 5:471-474, 1999.
Gura, T, Systems for identifying new drugs are often faulty. Science 278:1041-1042, 1997.
Afify et al., (1993) “Purification and Characterization of Human Serum Hyaluronidase” Arch. Biochem. Biophys. 305 (2):434-441.
Baumgartner et al., (1988) “Phase I Study in Chemoresistant Loco-regional Malignant Disease with Hyaluronidase” Reg. Cancer Treat. 1:55-58.
Beckenlehner et al., (1992) “Hyaluronidase Enhances the Activity of Adriamycin in Breast Cancer Models in Vitro and in Vivo” J. Cancer Res. Oncol. 118:591-596.
Bonner et al., (1966) “Colorimetric Method for Determination of Serum Hyaluronidase Activity” Clinica Chimica Acta 13:746-752.
Bordier, (1981) “Phase Separation of Integral Membrane Proteins in Triton X-114 Solution” J. Biol. Chem. 256(4):1604-1607.
Cashman et al., (1969) “The Hyaluronidase of Rat Skin” Arch. Biochem. Biophys. 135:387-395.
Czejka et al., (1990) “Influence o hyaluronidase on the blood plasma levels of 5-fluorouracil in patients,” Pharmazie 45:H.9.
De Maeyer et al., (1992) “The Growth Rate of Two Transplantable Murine Tumors, 3LL Lung Carcinoma and B16F10 Melanoma, Is Influenced by Hyal-1, A Locus Determining Hyaluronidase Levels and Polymorphism” Int. J. Cancer 51:657-660.
De Salegui et al., (1967) “A Comparison of Serum and Testicular Hyaluronidase” Arch. Biochem. Biophys. 121:548-554.
Delpech et al., (1987) “An Indirect Enzymoimmunology Assay for Hyaluronidase” J. Immunol. Methods 104:223-229.
Doctor et al., (1983) “Isolation and Properties of a New Anticoagulant Protein from Commercial Bovine Testicular Hyaluronidase” Thrombosis Res. 30:565-571.
Dorfman et al., (1948) “A Turbidimetric Method for the Assay of Hyalaronidase” J. Biol. Chem. 172:367-375.
Fenger et al (1982) “Purification of Human Serum Hyaluronidase Using Chromatofocusing.” (J. Chromatogr. 240:173-179).
Fiszer-Szafarz et al., (1989) “Hyal-1, a Locus Determining Serum Hyaluronidase Polymorphism, in Chromosome 9 in Mice” Somat. Cell. Mol. Genet. 15:79-83.
Fiszer-Szafarz et al., (1995) “Hyaluronidase in Human Somatic Tissues and Urine: Polymorphism and the Activity in Diseases,” Acta Biochim Pol. 42:31-3.
Gabizon (1995) “Stealth Liposomes and Cancer Targeting: A Realistic Compromise in Drug Delivery.” (J. Liposome Res., 5:704-710).
GenBank accession No. U03056, deposited Nov. 1, 1993.
Gregoriadis et al. (1993) “Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.” (Drugs, 45:15-28).
Guntenhoner et al., (1992) “A Substrate-Gel Assay for Hyaluronidase Activity” Matrix 12:388-396.
Harrison et al., (1988) “Multiple Forms of Ram and Bull Sperm Hyaluronidase Revealed by Using Monoclonal Antibodies” J. Reprod Fertil. 82:777-785.
Hegi et al., (1994) “Allelotype Analysis of Mouse lung Carcinomas Reveals Frequent Allelic Losses on Chromosome 4 and an Association between Allelic Imbalances on Chromosome 6 and K-ras Activation,” Cancer Research 54, pp. 6257-6264.
Horn et al., (1985) “Intravesical Chemotherapy of Superficial Bladder Tumors in a Controlled Trial with Cis-Platinum Versus Cis-Platinum Plus Hyaluronidase” J. Surg. Oncol. 28:304-307.
Johnstone et al. (1987) (Immunochemistry in Practice, Blackwell Scientific Publications, Oxford, pp. 30-31).
Kimata et al., (1983) “Increased Synthesis of Hyaluronic Acid by Mouse Mammary Carcinoma Cell Variants with High Metastatic Potential” Cancer Res. 43:1347-1354.
Kohno et al., (1994) “Effects of Hyaluronidase on Doxorubicin Penetration into Squamous Carcinoma Multicellular Tumor Spheroids and Its Cell Lethality” J. Cancer Res. Clin. Oncol. 120:293-297.
Kolarova et al., (1970) “Host-Tumour Relationship XXIX. Hyaluronidase Activity and Seromucoid Concentration in Blood Serum of Patients with Cancer” Neoplasma 17:641-648.
Komender et al., (1973) “Isolation of Hyaluronidase from Kidney Extract,” Bull Acad. Pol. Sci. (Biol.) 21:637-41.
Kreil, (1995) “Hyaluronidases—A Group of Neglected Enzymes” Protein Sci. 4:1666-1669.
Levvy et al., (1966) “Mammalian Glycosidases and Their Inhibition by Aldonolactones” Method Enzymol. 8:571-584.
Lien et al., (1990) “Collagen, Proteoglycan and Hyaluronidase Activity in Cultures from Normal and Scoliotic Chicken Fibroblasts” Biochim. Biophys. Acta. 1034:318-325.
Liu et al., (1996) “Expression of Hyaluronidase by Tumor Cells Induces Angiogenesis In Vivo” Proc. Natl. Acad. Sci. USA 93 (15):7832-7837.
Margolis et al., (1972) “The Hyaluronidase of Brain,” J. Neutrochem. 19:2325-32.
Natowicz et al., (1996) “Clinical and Biochemical Manifestations of Hyaluronidase Deficiency” N. Engl. J. Med. 335 (14):1029-1033.
Csóka Anthony
Frost Gregory I.
Stern Robert
Wong Tim M.
Borden Paula A.
Bozicevic, Field&FrancisLLP
Francis Carol L.
Nguyen Quang
The Regents of the University of California
LandOfFree
Use of human plasma hyaluronidase in cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of human plasma hyaluronidase in cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of human plasma hyaluronidase in cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3719930